FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

uniQure Reports Favorable Data in Huntingtons Trial

uniQure reports favorable data on its investigational gene therapy AMT-130 in Huntingtons disease patients.

latest-news-card-1
Human Drugs

University of Texas Clinical Trial Issues

FDA warns Dr. Ralph DeFronzo about violations in his work as a clinical investigator for two trial protocols at the University of Texas Health Science...

latest-news-card-1
Human Drugs

Harmony Reports Disappointing Fragile X Data

Harmony Biosciences reports topline results from a Phase 3 registrational clinical trial of ZYN002 in Fragile X syndrome did not meet the primary endp...

latest-news-card-1
Biologics

Cell/Gene Therapy Postapproval Monitoring Guide

FDA posts a draft guidance outlining methods drugmakers should use to collect long-term safety and efficacy data once cell and gene therapy products a...

Biologics

CGMP Violations at Janssen Vaccines S. Korea Plant

FDA warns Janssen Vaccines about CGMP violations in its Incheon, South Korea, drug manufacturing facility.

Human Drugs

CGMP Deviations in Chengdu Records Review

FDA warns Sichuan, China-based Chengdu Brilliant Biopharmaceutical Co. about CGMP deviations in its manufacturing of active pharmaceutical ingredients...

latest-news-card-1
Human Drugs

FDA Issues Complete Response Letter for Apitegromab

FDA issues Scholar Rock a complete response letter for its BLA seeking approval of apitegromab, indicated for treating spinal muscular atrophy.

latest-news-card-1
Medical Devices

Computer Software Assurance Guidance

FDA publishes a guidance with recommendations for computer software assurance in computers and automated data processing systems in medical device pro...

latest-news-card-1
Human Drugs

2 Items on Genzyme Ireland FDA-483

FDA releases the form FDA-483 with two observations from an inspection at the Genzyme Ireland drug manufacturing facility in Waterford, Ireland.

latest-news-card-1
Human Drugs

Cohance Lifescience FDA-483

FDA releases the form FDA-483 with six observations from an inspection at the Cohance Lifesciences drug manufacturing facility in Secunderabad, India.